Mannkind (MNKD) Total Non-Current Liabilities (2012 - 2026)
Mannkind (MNKD) reported Total Non-Current Liabilities of $798.5 million for Q1 2026, down 4.73% on a QoQ basis from $838.1 million in Q4 2025.
Mannkind (MNKD) has 15 years of Total Non-Current Liabilities data on file, last reported at $798.5 million in Q1 2026.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $798.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $798.5 million (changed N/A YoY) and the FY2025 annual result came in at $838.1 million, changed N/A from the prior year.
- Total Non-Current Liabilities retreated to $798.5 million in Q1 2026 per MNKD's latest filing, from $838.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $838.1 million in Q4 2025 and bottomed at -$55000.0 in Q4 2022.
- The 5-year median for Total Non-Current Liabilities is $553.5 million (2023), against an average of $526.4 million.
- The widest annual swing landed in 2022, when Total Non-Current Liabilities plunged 100.01%; it then surged 265107.27% in 2023.
- Tracing MNKD's Total Non-Current Liabilities over 5 years: stood at -$55000.0 in 2022, then surged by 265107.27% to $145.8 million in 2023, then jumped by 387.67% to $710.8 million in 2024, then climbed by 17.91% to $838.1 million in 2025, then dropped by 4.73% to $798.5 million in 2026.
- Per Business Quant, the three latest MNKD Total Non-Current Liabilities figures stand at $798.5 million (Q1 2026), $838.1 million (Q4 2025), and $710.8 million (Q1 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn | 798.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 798.45 Mn |
| Dec 31, 2025 | 838.09 Mn |
| Mar 31, 2024 | 710.79 Mn |
| Dec 31, 2023 | 145.75 Mn |
| Sep 30, 2023 | 572.05 Mn |
| Jun 30, 2023 | 573.85 Mn |
| Mar 31, 2023 | 553.48 Mn |
| Dec 31, 2022 | -55,000.00 |
| Sep 30, 2022 | 531.46 Mn |
| Jun 30, 2022 | 532.77 Mn |
| Mar 31, 2022 | 533.33 Mn |
| Dec 31, 2021 | 525.56 Mn |
| Sep 30, 2021 | 422.61 Mn |
| Jun 30, 2021 | 436.17 Mn |
| Mar 31, 2021 | 488.25 Mn |
| Dec 31, 2020 | 284.88 Mn |
| Sep 30, 2020 | 276.25 Mn |
| Jun 30, 2020 | 277.95 Mn |
| Mar 31, 2020 | 275.00 Mn |
| Dec 31, 2019 | 282.25 Mn |
| Jun 30, 2019 | 268.66 Mn |
| Mar 31, 2019 | 281.00 Mn |
| Dec 31, 2018 | 275.95 Mn |
| Sep 30, 2018 | 245.11 Mn |
| Jun 30, 2018 | 264.21 Mn |
| Mar 31, 2018 | 281.62 Mn |
| Dec 31, 2017 | 296.96 Mn |
| Sep 30, 2017 | 306.33 Mn |
| Jun 30, 2017 | 300.01 Mn |
| Mar 31, 2017 | 273.92 Mn |
| Dec 31, 2016 | 283.28 Mn |
| Sep 30, 2016 | 317.42 Mn |
| Jun 30, 2016 | 489.34 Mn |
| Mar 31, 2016 | 450.79 Mn |
| Dec 31, 2015 | 470.36 Mn |
| Sep 30, 2015 | 388.09 Mn |
| Jun 30, 2015 | 455.90 Mn |
| Mar 31, 2015 | 430.27 Mn |
| Dec 31, 2014 | 455.91 Mn |
| Sep 30, 2014 | 415.92 Mn |
| Jun 30, 2014 | 267.64 Mn |
| Mar 31, 2014 | 192.70 Mn |
| Dec 31, 2013 | 275.75 Mn |
| Sep 30, 2013 | 435.02 Mn |
| Jun 30, 2012 | 479.85 Mn |